Background: In high-risk prostate cancer (HR-PCA), it is important to consider the factors associated with extensive lymph node invasion (LNI) before planning treatment methods. Objective: To investigate clinical predictors of bilateral LNI in HR-PCA. Materials and Methods: The study evaluated 261 consecutive patients who underwent radical prostatectomy with extended pelvic lymph node dissection. The multivariate multinomial logistic regression model was computed. Results: The high-risk category included 102 cases. Overall, LNI was detected in 28 patients (27.5%) and was bilateral in 11 cases (10.8%). Independent factors associated with LNI were prostate-specific antigen (PSA) and proportion of positive cores. The main model showed that only higher values of PSA increased the odds of bilateral LNI when compared to patients having unilateral LNI (OR 1.058; p = 0.018). The area under the curve of PSA predicting bilateral LNI was 0.819. Conclusions: In HR-PCA, the independent predictor of LNI was PSA, which varied among patients with bilateral and unilateral LNI.

Keywords:
Prostate cancer, High risk, Lymph node invasion, Prostate-specific antigen, Tumor grading system, Prostate biopsy
1.
Gil-Vernet JM: Prostate cancer: anatomical and surgical considerations. Br J Urol 1996;78:161-168.
2.
Heidenreich A, Ohlmann CH, Polyakov S: Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 2007;52:29-37.
3.
Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, Montorsi F, Studer UE: Pelvic lymph node dissection in prostate cancer. Eur Urol 2009;55:1251-1265.
4.
Breyer BN, Greene KL, DallʼEra MA, Davies BJ, Kane CJ: Pelvic lymphadenectomy in prostate cancer. Prostate Cancer Prostatic Dis 2008;11:320-324.
5.
Ploussard G, Briganti A, de La Taille A, Haese A, Heidenreich A, Menon M, Sulser T, Tewari AK, Eastham JA: Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications - a systematic review of the literature. Eur Urol 2014;65:7-16.
6.
DʼAmico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.
7.
Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, Bianchi M, Sun M, Freschi M, Salonia A, Karakiewicz PI, Rigatti P, Montorsi F: Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 2012;61:480-487.
8.
Pierorazio PM, Walsh PC, Partin AW, Epstein JI: Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 2013;111:753-760.
9.
Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA: A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 2016;69:428-435.
10.
Moris L, Van den Broeck T, Tosco L, Van Baelen A, Gontero P, Karnes RJ, Everaerts W, Albersen M, Bastian PJ, Chlosta P, Claessens F, Chun FK, Graefen M, Gratzke C, Kneitz B, Marchioro G, Salas RS, Tombal B, Van Der Poel H, Walz JC, De Meerleer G, Bossi A, Haustermans K, Montorsi F, Van Poppel H, Spahn M, Briganti A, Joniau S: Impact of lymph node burden on survival of high-risk prostate cancer patients following radical prostatectomy and pelvic lymph node dissection. Front Surg 2016;3:65.
11.
Porcaro AB, de Luyk N, Corsi P, Sebben M, Tafuri A, Tamanini I, Processali T, Cerruto MA, Migliorini F, Brunelli M, Siracusano S, Artibani W: Bilateral lymph node micrometastases and seminal vesicle invasion associated with same clinical predictors in localized prostate cancer. Tumori 2016, Epub ahead of print.
12.
Menon M, Tewari A, Peabody J: Vattikuti Institute prostatectomy: technique. J Urol 2003;169:2289-2292.
13.
Walsh PC, Retik AB, Vaughan ED: Anatomic radical retropubic prostatectomy; in Campbellʼs Urology ed 8, Elsevier, Philadelphia 2002, vol 4, chapter 90, pp 3107-3129.
14.
Srigley JR, Humphrey PA, Amin MB, Chang SS, Egevad L, Epstein JI, Grignon DJ, McKiernan JM, Montironi R, Renshaw AA, Reuter VE, Wheeler TM: Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med 2009;133:1568-1576.
15.
Suardi N, Larcher A, Haese A, Ficarra V, Govorov A, Buffi NM, Walz J, Rocco B, Borghesi M, Steuber T, Pini G, Briganti A, Mottrie AM, Guazzoni G, Montorsi F, Pushkar D, Van Der Poel H: Indication for and extension of pelvic lymph node dissection during robot-assisted radical prostatectomy: an analysis of five European institutions. Eur Urol 2014;66:635-643.
16.
Yuh B, Artibani W, Heidenreich A, Kimm S, Menon M, Novara G, Tewari A, Touijer K, Wilson T, Zorn KC, Eggener SE: The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review. Eur Urol 2013;65:918-927.
17.
Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Seitz C, Sun M, Karakiewicz PI, Schramek P, Herman MP, Becker A, Hansen J, Ehdaie B, Loidl W, Pummer K, Lee RK, Lotan Y, Scherr DS, Seiler D, Ahyai SA, Chun FK, Graefen M, Tewari A, Nonis A, Bachmann A, Montorsi F, Gönen M, Briganti A, Shariat SF: Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment. Br J Cancer 2014;111:213-219.
18.
Abdollah F, Klett DE, Sood A, Sammon JD, Pucheril D, Dalela D, Diaz M, Peabody JO, Trinh QD, Menon M: Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram. BJU Int 2015;116:703-712.
19.
Sobin LH, Gospodariwicz M, Wittekind C: TNM classification of malignant tumors. International Union Against Cancer (UICC). Sobin MK, Gospodarowicz CH (ed). Wittekind7th. Oxford, UK Wiley-Blackwell, 2009.
20.
Muck A, Langesberg C, Mugler M, Rahnenfuhrer, Wullich B, Schafhauser W: Clinical outcome of patients with lymph node-positive prostate cancer following radical prostatectomy and extended sentinel lymph node dissection. Urol Int 2015;94:296-306.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.